デフォルト表紙
市場調査レポート
商品コード
1085285

ヒドロキシクロロキンの世界市場:適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析(2022年~2028年)

Hydroxychloroquine Market, By Disease Indication, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 145 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
ヒドロキシクロロキンの世界市場:適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析(2022年~2028年)
出版日: 2022年05月03日
発行: Coherent Market Insights
ページ情報: 英文 145 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

コロナウイルス感染症患者の治療に対するヒドロキシクロロキンの有効性を評価するため、主要企業が提携や共同研究などの無機的成長戦略を増加させていることは、予測期間中のヒドロキシクロロキン市場の成長を促進するものと期待されます。

当レポートでは、世界のヒドロキシクロロキン市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場の内訳:適応症別
    • 市場の内訳:流通チャネル別
    • 市場の内訳:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 規制シナリオ
  • 業界動向
  • 合併と買収
  • 新しい疾患適応症の承認/発売
  • プロモーションおよびマーケティングイニシアチブ
  • PEST分析

第1章 世界のヒドロキシクロロキン市場:適応症別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • マラリア
  • コロナウイルス病
  • エリテマトーデス
  • 関節リウマチ

第2章 世界のヒドロキシクロロキン市場:流通チャネル別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第3章 世界のヒドロキシクロロキン市場:地域別(100万米ドル)(2017年~2028年)

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第4章 競合情勢

  • ヒートマップ分析
  • 市場シェア分析
    • Sanofi SA
    • 適応症ポートフォリオ
    • Amneal Pharmaceuticals, Inc.
    • 適応症ポートフォリオ
    • Laurus Labs Limited
    • 適応症ポートフォリオ
    • Zydus Pharmaceuticals, Inc.
    • 適応症ポートフォリオ
    • Prasco Laboratories
    • 適応症ポートフォリオ
    • Dr. Reddy's Laboratories
    • 適応症ポートフォリオ
    • Cadila Pharmaceuticals
    • 適応症ポートフォリオ
    • Novartis International AG
    • 適応症ポートフォリオ
    • Concordia Pharmaceuticals Inc.
    • 適応症ポートフォリオ
    • Covis Pharmaceuticals, Inc.
    • 適応症ポートフォリオ
    • Cardinal Health
    • 適応症ポートフォリオ
    • Aphena Pharma Solutions Tennessee, Inc.
    • 適応症ポートフォリオ
    • Mylan NV
    • 適応症ポートフォリオ
    • McKesson Corporation
    • 適応症ポートフォリオ
    • Teva Pharmaceutical Industries Ltd
    • 適応症ポートフォリオ
    • Lupin Pharmaceutical
    • 適応症ポートフォリオ
    • Sun Pharmaceutical Industries Ltd
    • 適応症ポートフォリオ
  • アナリストの見解

第5章 セクション

目次
Product Code: CMI3727

Hydroxychlorquine has exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.

Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2022, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).

Key features of the study:

  • This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hydroxchloroquine market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics
  • The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market

Detailed Segmentation:

  • Global Hydroxchloroquine Market, By Disease Indication:
    • Malaria
    • Coronavirus disease (COVID 19)
    • Lupus Erythematosus
    • Rheumatoid Arthritis
  • Global Hydroxchloroquine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hydroxchloroquine Market, By Region:
    • North America
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Disease Indication:
      • Malaria
      • Coronavirus disease (COVID 19)
      • Lupus Erythematosus
      • Rheumatoid Arthritis
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Sanofi S.A.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Amneal Pharmaceuticals, Inc.
    • Laurus Labs Limited
    • Zydus Pharmaceuticals, Inc.
    • Prasco Laboratories
    • Dr. Reddy's Laboratories
    • Cadila Pharmaceuticals
    • Novartis International AG
    • Concordia Pharmaceuticals Inc.
    • Covis Pharmaceuticals, Inc.
    • Cardinal Health
    • Aphena Pharma Solutions Tennessee, Inc.
    • Mylan N.V.
    • McKesson Corporation
    • Teva Pharmaceutical Industries Ltd
    • Lupin Pharmaceutical
    • Sun Pharmaceutical Industries Ltd

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Industry Trend
  • Merger and Acquisitions
  • New Disease Indication Approvals/Launch
  • Promotion and Marketing Initiatives
  • PEST Analysis

1. Global Hydroxychloroquine Market, By Disease Indication, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Malaria
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Coronavirus Disease (COVID 19)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Lupus Erythematosus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Rheumatoid Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

2. Global Hydroxychloroquine Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

3. Global Hydroxychloroquine Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Disease Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

4. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Sanofi S.A.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amneal Pharmaceuticals, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Laurus Labs Limited
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Zydus Pharmaceuticals, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Prasco Laboratories
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cadila Pharmaceuticals
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis International AG
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Concordia Pharmaceuticals Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Covis Pharmaceuticals, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cardinal Health
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Aphena Pharma Solutions Tennessee, Inc.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan N.V.
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • McKesson Corporation
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Lupin Pharmaceutical
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sun Pharmaceutical Industries Ltd
    • Company Overview
    • Disease Indication Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

5. Section

  • References
  • Research Methodology
  • About us and Sales Contact